Genmab receives orphan drug designation from FDA

The US Health authority has granted orphan drug status to Genmab’s lymphoma treatment, epcoritamab, which is being developed alongside Abbvie.
Photo: Tuala Hjarnø / Genmab / PR
Photo: Tuala Hjarnø / Genmab / PR
by marketwire, translated by daniel pedersen

Danish biotech company Genmab announces in a press release that the US Food and Drug Administration (FDA) has designated the company’s investigational drug, epcoritamab, an orphan drug.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading